Urinary Neutrophil Gelatinase-Associated Lipocalin Levels in Comparison with Glomerular Filtration Rate for Evaluation of Renal Function in Patients with Diabetic Chronic Kidney Disease

Article information

Diabetes Metab J. 2012;36(4):307-313

Publication date (electronic) : 2012 August 20

doi : https://doi.org/10.4093/dmj.2012.36.4.307

Kwang-Sook Woo ¹, Jae-Lim Choi ¹, Bo-Ram Kim ¹, Ji-Eun Kim ¹, Won-Suk An ², Jin-Yeong Han ¹

¹Department of Laboratory Medicine, Dong-A University College of Medicine, Busan, Korea.

²Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea.

Corresponding author: Jin-Yeong Han. Department of Laboratory Medicine, Dong-A University College of Medicine, 32 Daesingongwon-ro, Seo-gu, Busan 602-714, Korea. jyhan@dau.ac.kr

Received 2012 February 13; Accepted 2012 April 16.

Abstract

Background

Neutrophil gelatinase-associated lipocalin (NGAL) is a promising biomarker of acute kidney injury. There is a growing body of evidence suggesting that NGAL is also a marker of kidney disease and severity in chronic kidney disease (CKD). We studied the utility of urinary NGAL in more accurately predicting renal function in patients with diabetic CKD.

Methods

We studied possible relationships between urinary NGAL, estimated glomerular filtration rate (eGFR), and proteinuria in diabetic CKD patients and in healthy populations.

Results

Urinary NGAL levels were significantly higher in CKD patients than in healthy controls (96.0 [2.7 to 975.2] ng/mL vs. 18.8 [1.3 to 81.9] ng/mL, P=0.02), and the GFR was lower among CKD patients (49.3 [13.1 to 78.3] mL/min/1.73 m² vs. 85.6 [72 to 106.7] mL/min/1.73 m², P<0.0001). The urinary NGAL level showed a significant inverse correlation with GFR (r=-0.5634, P<0.0001). The correlation analyses between urinary protein level and urinary NGAL levels and GFR were as follows: urine protein and urinary NGAL (r=0.3009, P=0.0256), urine protein and GFR (r=-0.6245, P<0.0001), urine microalbumin and urinary NGAL (r=0.1794, P=0.2275), and urine microalbumin and GFR (r=-0.5190, P=0.0002).

Conclusion

From these results, we concluded that urinary NGAL is a reliable marker of renal function in diabetic CKD patients. However, urinary NGAL did not provide more accurate information regarding renal function than GFR.

Keywords: Chronic kidney disease; Glomerular filtration rate; Neutrophil gelatinase-associated lipocalin

INTRODUCTION

Neutrophil gelatinase-associated lipocalin (NGAL) is a member of the lipocalin family that is expressed at low levels in several human tissues and rapidly released from renal tubular cells in response to various insults to the kidney [1,2]. Serum and urinary NGAL are arguably the most promising emerging biomarkers for early detection of acute kidney injury (AKI) [3-7]. Several recent studies have also defined the role of NGAL in chronic kidney disease (CKD) and showed serum and urinary NGAL levels are a marker of kidney disease and severity in CKD [8-12]. In addition, though all forms of CKD are also associated with tubulointerstitial injury, regardless of whether the primary pathology is glomerular or otherwise, it is now widely accepted that in some CKD-associated diseases, such as diabetic nephropathy, the rate of deterioration in renal function and the overall outcome are more accurately associated with the degree of renal tubulointerstitial damage than with the severity of glomerular lesions. These factors suggest that NGAL may have unique predictive value in diabetic nephropathy.

In our study, we assessed urinary NGAL levels in diabetic CKD in order to study whether urinary NGAL is a sensitive biomarker of kidney function in this disease.

METHODS

This study was a single-center, cross-sectional study of patients with diabetic CKD. This study included 56 samples from 31 diabetic CKD patients for whom a serum creatinine and random urine protein test had been requested and 36 samples from healthy populations seen at Dong-A University Hospital between June 2009 and September 2010. Inclusion criterion was the presence of stage 3 to 5 CKD according to the National Kidney Foundation's classification. Patients who were free of cancer and liver, thyroid, or infectious diseases at the time of the study were included. The average duration of diabetes for this group was 14.3 years. The healthy population consisted of samples obtained from the people who visited the hospital for periodic medical checkups and proved to have no specific clinical or laboratory problems. Informed consent was obtained and urine samples were collected. Fresh serum and urine samples were tested for creatinine, glomerular filtration rate (GFR), urinary albumin, and protein at the requested time. Urine protein and albumin were measured by TBA-200FR (TBA-200FR; Toshiba Medical Systems, Tokyo, Japan) and urine albumin/creatinine ratio (UACR) was calculated. The GFR level was calculated using the MDRD formula: MDRD=186×(serum creatinine [mg/dL])-1.154×age^-0.203 [13]. A correction factor of 0.742 was used for women. Urine samples were then stored at -70℃ until further testing. Urinary NGAL was measured simultaneously by ARCHITECT NGAL assay (Abbott Laboratories, Abbott Park, IL, USA) implemented on an Abbott Architect immunoanalyzer. All charts of CKD patients and healthy individuals were reviewed. Correlations between urinary NGAL and other variables were evaluated by Pearson's or Spearman's test as appropriate. The statistical analysis was performed using MedCalc version 9.3 (MedCalc Software, Mariakerke, Belgium). P values of less than 0.05 were regarded as statistically significant.

RESULTS

The characteristics of the study cohort are presented in Table 1. Mean age of the patients (11 females and 20 males [ratio, 1:2]) was 62.4±10.2 years. Mean serum creatinine was 1.66±0.82 mg/dL with a mean GFR of 49.3±17.5 mL/min/1.73 m² (range, 13.1 to 78.3). The mean urinary NGAL level of the CKD patients was significantly higher than that measured in healthy controls (96.0 [2.7 to 975.2] ng/mL vs. 18.8 [1.3 to 81.9] ng/mL, P=0.02) and GFR was lower than those in healthy controls (49.3 [13.1 to 78.3] mL/min/1.73 m² vs. 85.6 [72 to 106.7] mL/min/1.73 m², P<0.0001) (Fig. 1).

Table 1

Demographic data of 31 patients and 36 healthy individuals

Fig. 1

Urinary neutrophil gelatinase-associated lipocalin (NGAL) levels and glomerular filtration rate (GFR) in patients and healthy populations. (A) NGAL levels: 18.8 (1.3 to 81.9) ng/mL vs. 96.0 (2.7 to 975.2) ng/mL (P=0.02). (B) GFR: 49.3 (13.1 to 78.3) mL/min/1.73 m² vs. 85.6 (72 to 106.7) mL/min/1.73 m² (P<0.0001). CKD, chronic kidney disease.

Correlation between GFR and urinary NGAL levels

The correlation analyses between GFR and urinary NGAL levels in CKD patients are presented in Fig. 2. The urinary NGAL level showed a significant inverse correlation with GFR in CKD patients (r=-0.5634, P<0.0001).

Fig. 2

Correlation analysis between glomerular filtration rate (GFR) and urinary neutrophil gelatinase-associated lipocalin (NGAL) in chronic kidney disease patients (r=-0.5634, P<0.0001).

Correlation between urinary protein level and urinary NGAL and GFR

The correlation analyses between urinary protein and urinary NGAL levels in CKD patients are presented in Fig. 3. The correlation between urinary protein and urinary NGAL levels and GFR in patients were as follows: urine protein and urinary NGAL (r=0.3009, P=0.0256), urine protein and GFR (r=-0.6245, P<0.0001), urine albumin and urinary NGAL (r=0.1794, P=0.2275), and urine albumin and GFR (r=-0.5190, P=0.0002). The urinary NGAL level was significantly correlated with the amount of urinary protein excretion in CKD patients. GFR, like urinary NGAL, also showed a strong correlation with the extent of urinary protein, including albumin, but the level of correlation with GFR was even greater in CKD patients in our study. In addition, only GFR showed a negative correlation with UACR (r=0.5497, P=0.0001). Urinary NGAL, however, was not correlated with UACR.

Fig. 3

Correlation analyses for urine protein and urinary neutrophil gelatinase-associated lipocalin (NGAL) levels and glomerular filtration rate (GFR) in chronic kidney disease patients. Correlations were analyzed between urinary protein level and urinary NGAL level (A) (r=0.3009, P=0.0256), urine protein and GFR (B) (r=-0.6245, P<0.0001), urine albumin and urinary NGAL (C) (r=0.1794, P=0.2275), and urine albumin and GFR (D) (r=-0.5190, P=0.0002).

Correlation between the age, sex, and GFR and urinary NGAL in the control group

In the analyses with the control subjects, no significant correlation was observed between urinary NGAL levels and other variables (Fig. 4).

Fig. 4

Correlation between age (A) (r=-0.1488, P=0.3866), sex (B) (P=0.1823), and glomerular filtration rate (GFR) (C) (r=-0.2621, P=0.1226) and urinary neutrophil gelatinase-associated lipocalin (NGAL) in healthy populations.

DISCUSSION

Many clinical studies have demonstrated the utility of NGAL as a specific, sensitive, and early predictor of AKI [3-7]. In CKD, there are also many reports suggesting that NGAL is also a novel, independent marker of disease progression that provides a good reflection of the severity of renal disease. A variety of clinical settings have been examined, including cardiac surgery, contrast administration, septic shock, intensive care units, the emergency department, and even renal transplantation [7,14-22]. In one study of CKD patients secondary to renal dysplasia, obstructive uropathy, and glomerular and cystic diseases, plasma NGAL concentrations were inversely associated with GFR [8]. Another study in subjects with CKD (due to chronic glomerulonephritis) showed that mean urinary NGAL concentrations were higher in CKD patients (378.28±111.13 µg/L vs. 7.38±3.26 µg/L in controls, P=0.01). Furthermore, urinary NGAL concentrations were significantly correlated with GFR (r=-0.528, P=0.04) and proteinuria (r=0.294, P=0.01) [10]. In a study of 80 non-diabetic patients with CKD stages 2 to 4, 80 kidney transplant recipients, and 32 healthy control subjects, the investigators found that serum NGAL values were significantly higher in kidney allograft recipients and patients with CKD compared with healthy controls. NGAL rose gradually, reaching the highest value in advanced CKD [22]. In addition, Bolignano et al. [12] measured NGAL in a cohort of patients affected by non-advanced CKD with stable renal function. A strict, independent, and inverse correlation with GFR was described for both serum and urinary NGAL, suggesting that urinary and serum NGAL predicted CKD progression independent of age and GFR. Recently, several reports showed conflicting results concerning the correlation between increased tubular makers, including urinary NGAL, and disease progression in diabetic patients. Fu et al. [23] measured several markers of renal damage, especially tubular markers, including urinary NGAL. In one study including 101 type 2 diabetic patients, they categorized patients into three groups according to their UACR and compared tubular markers with renal indices, such as UACR and GFR. Urinary NGAL showed a positive correlation with UACR and a negative correlation with GFR [24]. In our study, urinary NGAL also showed a negative correlation with GFR. However, there was no statistically significant correlation between urinary NGAL and UACR. In the study of Fu et al., they categorized patients into two groups according to GFR and excluded the lower GFR group, and they observed that higher urinary tubular damage markers were found in type 2 diabetic patients with glomerular hyperfiltration (GHF) than in the normal GFR and control groups. GHF is known to play a crucial role in the progression of diabetic nephropathy and has been regarded as a risk factor for the development of microalbuminuria. However, in contrast to that previous study, the present study included patients with diabetic CKD and overt albuminuria, and their baseline GFR was 49.3 mL/min/1.73 m². GHF has been regarded as a risk factor for the initiation and development of microalbuminuria. This explains why our study did not show an effect of GHF when evaluating tubular damage markers, such as urinary NGAL, even though NGAL was negatively correlated with GFR. However, few studies have reported that tubular damage markers are not predictive of the decline in GFR in diabetic patients. Nielsen et al. [25] reported a lack of an independent correlation between these biomarkers and GFR in diabetic patients. Their study included type 1 diabetic patients with overt nephropathy, but our study included type 2 diabetic patients and showed a negative correlation between urinary NGAL and GFR without adjustment.

The results of our study showed that urinary NGAL levels were significantly elevated in diabetic CKD patients compared to the normal control group. These results were consistent with previous reports indicating increased serum and urinary NGAL levels in CKD patients with decreased GFR [8,10-12]. A significant inverse correlation was also observed between urinary NGAL level and GFR in CKD patients, similar to what has previously been described elsewhere [10-12]. We also analyzed for a correlation between NGAL and the amount of urinary excretion of protein, including albumin. Previous reports have shown a direct correlation between proteinuria and urinary NGAL level [10,11,26]. Consistent with these reports, we observed a significant correlation between urinary NGAL levels and the level of urinary protein excretion, excluding albumin, in CKD patients. These results suggest that NGAL could be a marker of renal function in patients with diabetic CKD.

We also analyzed the correlation between GFR and the amount of urinary protein excretion and observed a significant correlation with the amount of urinary protein excretion, including both albumin and protein, and the levels of correlation were higher than for urinary NGAL. Fig. 1 shows that GFR was significantly lower in CKD patients than in healthy controls, and the level of difference was higher than for urinary NGAL. Therefore, our study did not demonstrate that the rate of deterioration in renal function in diabetic CKD patients is more accurately associated with the degree of renal tubulointerstitial damage than with the severity of glomerular lesions. Though there are many studies suggesting that creatinine and GFR based on creatinine show low accuracy for measuring of renal function, GFR is still thought to be a reliable marker for estimating renal function in our study [27,28].

Our study has some potential limitations. The small population in our study, selection of the control group, ethnic differences, and differences in methods for evaluating urinary NGAL may have influenced the results. Additionally, the pathogenesis of diabetic kidney disease is complex and multifactorial. The duration of diabetes among the patients varied and hemodynamic changes could occur in the glomeruli causing glomerular hyperfiltration and altered vascular endothelial tone, which are related to GFR and urinary NGAL levels [29]. Medications were not evaluated in this study. Our study only included diabetic CKD patients and healthy individuals. In addition, urinary NGAL and the serum creatinine were measured only once in a small population, and we could not rule out intra-patient variability or analyze for correlation between urinary NGAL and disease progression. However, our results were similar to results of previous reports that have demonstrated a strong correlation between GFR and urinary NGAL and that urinary NGAL is not influenced by age and gender.

In conclusion, we conclude that urinary NGAL is a reliable marker of renal function in diabetic CKD patients. Despite a good correlation between GFR and the amount of urinary protein excretion and urinary NGAL, urinary NGAL provided no additional information regarding renal function compared with GFR as a routine laboratory test for diabetic CKD patients. Future studies in different clinical settings with larger numbers of patients and healthy individuals are necessary to clarify the effectiveness of urinary NGAL in determining renal function and disease progression.

ACKNOWLEDGMENTS

This work was supported by the Dong-A University research fund.

Notes

No potential conflict of interest relevant to this article was reported.

References

1. Venge P, Carlson M, Fredens K, Garcia R. The 40 kD-protein. A new protein isolated from the secondary granules of human neutrophils: Joint International Conference on Leukocyte Biology. J Leukocyte Biol 1990;(Suppl 1):28.

2. Allen RA, Erickson RW, Jesaitis AJ. Identification of a human neutrophil protein of Mr 24 000 that binds N-formyl peptides: co-sedimentation with specific granules. Biochim Biophys Acta 1989;991:123–133. 2653446.

3. Mishra J, Ma Q, Prada A, Mitsnefes M, Zahedi K, Yang J, Barasch J, Devarajan P. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 2003;14:2534–2543. 14514731.

4. Mishra J, Mori K, Ma Q, Kelly C, Barasch J, Devarajan P. Neutrophil gelatinase-associated lipocalin: a novel early urinary biomarker for cisplatin nephrotoxicity. Am J Nephrol 2004;24:307–315. 15148457.

5. Mishra J, Dent C, Tarabishi R, Mitsnefes MM, Ma Q, Kelly C, Ruff SM, Zahedi K, Shao M, Bean J, Mori K, Barasch J, Devarajan P. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 2005;365:1231–1238. 15811456.

6. Trachtman H, Christen E, Cnaan A, Patrick J, Mai V, Mishra J, Jain A, Bullington N, Devarajan P. Investigators of the HUS-SYNSORB Pk Multicenter Clinical Trial. Urinary neutrophil gelatinase-associated lipocalcin in D+HUS: a novel marker of renal injury. Pediatr Nephrol 2006;21:989–994. 16773412.

7. Hirsch R, Dent C, Pfriem H, Allen J, Beekman RH 3rd, Ma Q, Dastrala S, Bennett M, Mitsnefes M, Devarajan P. NGAL is an early predictive biomarker of contrast-induced nephropathy in children. Pediatr Nephrol 2007;22:2089–2095. 17874137.

8. Mitsnefes MM, Kathman TS, Mishra J, Kartal J, Khoury PR, Nickolas TL, Barasch J, Devarajan P. Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in children with chronic kidney disease. Pediatr Nephrol 2007;22:101–108. 17072653.

9. Suzuki M, Wiers KM, Klein-Gitelman MS, Haines KA, Olson J, Onel KB, O'Neil K, Passo MH, Singer NG, Tucker L, Ying J, Devarajan P, Brunner HI. Neutrophil gelatinase-associated lipocalin as a biomarker of disease activity in pediatric lupus nephritis. Pediatr Nephrol 2008;23:403–412. 18202859.

10. Bolignano D, Coppolino G, Campo S, Aloisi C, Nicocia G, Frisina N, Buemi M. Urinary neutrophil gelatinase-associated lipocalin (NGAL) is associated with severity of renal disease in proteinuric patients. Nephrol Dial Transplant 2008;23:414–416. 17893105.

11. Bolignano D, Lacquaniti A, Coppolino G, Campo S, Arena A, Buemi M. Neutrophil gelatinase-associated lipocalin reflects the severity of renal impairment in subjects affected by chronic kidney disease. Kidney Blood Press Res 2008;31:255–258. 18600028.

12. Bolignano D, Lacquaniti A, Coppolino G, Donato V, Campo S, Fazio MR, Nicocia G, Buemi M. Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. Clin J Am Soc Nephrol 2009;4:337–344. 19176795.

13. Myers GL, Miller WG, Coresh J, Fleming J, Greenberg N, Greene T, Hostetter T, Levey AS, Panteghini M, Welch M, Eckfeldt JH. National Kidney Disease Education Program Laboratory Working Group. Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education Program. Clin Chem 2006;52:5–18. 16332993.

14. Tuladhar SM, Puntmann VO, Soni M, Punjabi PP, Bogle RG. Rapid detection of acute kidney injury by plasma and urinary neutrophil gelatinase-associated lipocalin after cardiopulmonary bypass. J Cardiovasc Pharmacol 2009;53:261–266. 19247188.

15. Xin C, Yulong X, Yu C, Changchun C, Feng Z, Xinwei M. Urine neutrophil gelatinase-associated lipocalin and interleukin-18 predict acute kidney injury after cardiac surgery. Ren Fail 2008;30:904–913. 18925531.

16. Wagener G, Jan M, Kim M, Mori K, Barasch JM, Sladen RN, Lee HT. Association between increases in urinary neutrophil gelatinase-associated lipocalin and acute renal dysfunction after adult cardiac surgery. Anesthesiology 2006;105:485–491. 16931980.

17. Bennett M, Dent CL, Ma Q, Dastrala S, Grenier F, Workman R, Syed H, Ali S, Barasch J, Devarajan P. Urine NGAL predicts severity of acute kidney injury after cardiac surgery: a prospective study. Clin J Am Soc Nephrol 2008;3:665–673. 18337554.

18. Dent CL, Ma Q, Dastrala S, Bennett M, Mitsnefes MM, Barasch J, Devarajan P. Plasma neutrophil gelatinase-associated lipocalin predicts acute kidney injury, morbidity and mortality after pediatric cardiac surgery: a prospective uncontrolled cohort study. Crit Care 2007;11:R127. 18070344.

19. Bachorzewska-Gajewska H, Malyszko J, Sitniewska E, Malyszko JS, Pawlak K, Mysliwiec M, Lawnicki S, Szmitkowski M, Dobrzycki S. Could neutrophil-gelatinase-associated lipocalin and cystatin C predict the development of contrast-induced nephropathy after percutaneous coronary interventions in patients with stable angina and normal serum creatinine values? Kidney Blood Press Res 2007;30:408–415. 17901710.

20. Makris K, Markou N, Evodia E, Dimopoulou E, Drakopoulos I, Ntetsika K, Rizos D, Baltopoulos G, Haliassos A. Urinary neutrophil gelatinase-associated lipocalin (NGAL) as an early marker of acute kidney injury in critically ill multiple trauma patients. Clin Chem Lab Med 2009;47:79–82. 19055468.

21. Nickolas TL, O'Rourke MJ, Yang J, Sise ME, Canetta PA, Barasch N, Buchen C, Khan F, Mori K, Giglio J, Devarajan P, Barasch J. Sensitivity and specificity of a single emergency department measurement of urinary neutrophil gelatinase-associated lipocalin for diagnosing acute kidney injury. Ann Intern Med 2008;148:810–819. 18519927.

22. Malyszko J, Malyszko JS, Bachorzewska-Gajewska H, Poniatowski B, Dobrzycki S, Mysliwiec M. Neutrophil gelatinase-associated lipocalin is a new and sensitive marker of kidney function in chronic kidney disease patients and renal allograft recipients. Transplant Proc 2009;41:158–161. 19249502.

23. Fu WJ, Li BL, Wang SB, Chen ML, Deng RT, Ye CQ, Liu L, Fang AJ, Xiong SL, Wen S, Tang HH, Chen ZX, Huang ZH, Peng LF, Zheng L, Wang Q. Changes of the tubular markers in type 2 diabetes mellitus with glomerular hyperfiltration. Diabetes Res Clin Pract 2012;95:105–109. 22015481.

24. Fu WJ, Xiong SL, Fang YG, Wen S, Chen ML, Deng RT, Zheng L, Wang SB, Pen LF, Wang Q. Urinary tubular biomarkers in short-term type 2 diabetes mellitus patients: a cross-sectional study. Endocrine 2012;41:82–88. 21779943.

25. Nielsen SE, Andersen S, Zdunek D, Hess G, Parving HH, Rossing P. Tubular markers do not predict the decline in glomerular filtration rate in type 1 diabetic patients with overt nephropathy. Kidney Int 2011;79:1113–1118. 21270761.

26. Bolignano D, Coppolino G, Lacquaniti A, Nicocia G, Buemi M. Pathological and prognostic value of urinary neutrophil gelatinase-associated lipocalin in macroproteinuric patients with worsening renal function. Kidney Blood Press Res 2008;31:274–279. 18753796.

27. Perrone RD, Madias NE, Levey AS. Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem 1992;38:1933–1953. 1394976.

28. Lawson N, Lang T, Broughton A, Prinsloo P, Turner C, Marenah C. Creatinine assays: time for action. Ann Clin Biochem 2002;39(Pt 6):599–602. 12564843.

29. Bank N. Mechanisms of diabetic hyperfiltration. Kidney Int 1991;40:792–807. 1745032.

Article information Continued

(open-access, http://creativecommons.org/licenses/by-nc/3.0/) :

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.